A 68-year-old woman with chronic atrial fibrillation and a left ventricular ejection fraction of 35% is admitted with acute decompensated heart failure. Her heart rate is 110 bpm, and she is hypotensive (systolic BP 90 mmHg). An ECG confirms atrial fibrillation with rapid ventricular response. Intravenous diuretics and vasodilators have been initiated, but the tachycardia persists. What is the most appropriate next step in rate control?

Explanation

## Clinical Context: Reduced Ejection Fraction with Rapid AF This patient presents with **acute decompensated heart failure (HF with reduced ejection fraction [HFrEF])** and rapid atrial fibrillation. The critical constraint is **hemodynamic instability** (hypotension, signs of decompensation) combined with **severely reduced LV function (EF 35%)**. ## Why Calcium Channel Blockers Are Contraindicated **Key Point:** Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) are **absolutely contraindicated** in HFrEF because they: 1. Have negative inotropic effects (reduce myocardial contractility) 2. Cause vasodilation and worsen hypotension 3. Can precipitate cardiogenic shock in patients with reduced EF 4. Increase mortality in HFrEF populations **High-Yield:** The 2019 ACC/AHA Heart Failure Guidelines explicitly recommend **against** calcium channel blockers for rate control in HFrEF with AF. ## Rationale for Intravenous Amiodarone **Clinical Pearl:** Amiodarone is the **Class III antiarrhythmic of choice** for rate control in hemodynamically unstable patients with HFrEF because it: 1. **Minimal negative inotropy** — despite being a Class III agent, amiodarone has less myocardial depression than other antiarrhythmics 2. **Vasodilatory properties** — helps maintain systemic perfusion 3. **Dual rate control and rhythm conversion** — can restore sinus rhythm in some patients 4. **Safe in reduced EF** — extensively studied in HFrEF populations 5. **Effective in acute decompensation** — IV formulation allows rapid loading **Mnemonic:** **ABCD of antiarrhythmics in HFrEF:** - **A**void calcium channel blockers - **B**eta-blockers (if tolerated) - **C**lass III agents (amiodarone preferred) - **D**igoxin (if beta-blockers contraindicated) ## Comparison of Rate Control Options in HFrEF | Agent | Class | Mechanism | EF <40%? | Hemodynamic Effect | Use in Acute HF? | |-------|-------|-----------|---------|-------------------|------------------| | Verapamil | IV | AV nodal block | **NO** | ↓ Contractility, ↓ BP | Contraindicated | | Diltiazem | IV | AV nodal block | **NO** | ↓ Contractility, ↓ BP | Contraindicated | | Amiodarone | III | K^+^ channel block | **YES** | Neutral/mild vasodilation | **First-line** | | Digoxin | Vagomimetic | AV nodal block | YES | Neutral/mild ↑ contractility | Second-line | ## Treatment Algorithm for Rapid AF in HFrEF ```mermaid flowchart TD A[Atrial fibrillation + HFrEF]:::outcome --> B{Hemodynamically stable?}:::decision B -->|Yes| C[Oral beta-blocker or digoxin]:::action B -->|No| D{Acute decompensation?}:::decision D -->|Yes| E[IV Amiodarone 150 mg over 10 min]:::action D -->|No| F[IV Digoxin 0.5 mg over 30 min]:::action E --> G[Monitor HR, BP, EKG]:::action F --> G G --> H{Rate controlled?}:::decision H -->|Yes| I[Continue IV infusion or transition to oral]:::outcome H -->|No| J[Repeat amiodarone or consider cardioversion]:::action ``` **Warning:** Do NOT use verapamil or diltiazem in this patient. These agents will worsen hypotension and precipitate cardiogenic shock.